Q-omics provides the consensus-scored RGPD3 profile across patient tissues and cancer cell-line models. RGPD3 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, RGPD3 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, RGPD3 RNA expression shows 17,016 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BRCA, KIRC, and UVM as cancer lineages where RGPD3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RGPD3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RGPD3 survival associations across molecular data types. RGPD3 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RGPD3 RNA expression–survival associations across cancer types. High RGPD3 expression shows unfavorable associations in ESCA, but favorable associations in BRCA, LAML, SCLC, LUAD and LGG. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .005). Together, the overview and detailed table identify BRCA as the clearest survival context for RGPD3 RNA expression.
This table summarizes RGPD3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for RGPD3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RGPD3 shows lower tumor expression in KIRC, KIRP, CHOL, THCA and KICH and higher tumor expression in PRAD. The KIRC box plot shows higher RGPD3 RNA expression in normal versus tumor tissue (log2 FC = −0.200, t-test p < 0.001).
This table shows molecular features associated with RGPD3 in patient tissues and cancer cell lines. In patient samples, RGPD3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RGPD3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and LARGE_INTESTINE.
